Ebglyss 250 mg Pen: Uses, Dosage and Safety

What is Ebglyss?

Ebglyss is the brand name for lebrikizumab, a monoclonal antibody that binds to interleukin-13 (IL-13). IL-13 contributes to the inflammation involved in atopic dermatitis. Blocking its signalling can reduce eczema severity and itching.

Each single-use pre-filled pen contains 250 mg in 2 mL, equivalent to 125 mg/mL. A pre-filled syringe presentation also exists; device instructions are not interchangeable.

What is Ebglyss used for?

In the European Union and United Kingdom, Ebglyss is authorised for moderate-to-severe atopic dermatitis in adults and adolescents aged 12 years and older who weigh at least 40 kg and are candidates for systemic therapy.

In the United States, Ebglyss is authorised for the same age and weight group when atopic dermatitis is not adequately controlled with topical prescription therapies or when those therapies are not advisable. These criteria should not be presented as a universal indication.

Ebglyss can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used for particular areas when advised by the prescriber.

Official dosage schedule

The current EU, UK and US labels use the following schedule for eligible adults and adolescents:

• Week 0: 500 mg, given as two 250 mg injections.
• Week 2: 500 mg, again given as two 250 mg injections.
• After week 2: 250 mg every two weeks through week 16.
• After an adequate clinical response: 250 mg every four weeks as maintenance.

EU and UK product information advises considering discontinuation if there is no clinical response after 16 weeks, although some people with a partial initial response may improve with every-two-week treatment through week 24. Treatment response and any change to the schedule must be assessed by the prescriber.

How to use the pre-filled pen

A patient or caregiver may give Ebglyss after a healthcare professional decides that self-injection is appropriate and provides training. Read the country-specific Instructions for Use each time the device or packaging changes.

• Inject under the skin of the thigh or abdomen, avoiding the area around the navel described in the leaflet.
• A caregiver may also inject into the back of the upper arm.
• Rotate sites and avoid skin that is tender, damaged, bruised or scarred, or affected by atopic dermatitis.
• When two injections are required, use two different injection sites.
• Do not shake the pen, and do not use it if the medicine is frozen, cloudy, discoloured or contains particles.
• Place each used pen in an approved sharps container.

Do not rely on a general web article for device operation. The illustrated Instructions for Use supplied with the exact pen are the controlling instructions.

Storage

Store Ebglyss in a refrigerator at 2°C to 8°C, in its original carton to protect it from light. Do not freeze it and do not expose it to heat or direct sunlight.

Current EU, UK and US information permits storage at room temperature up to 30°C for no more than 7 days. Once removed from refrigeration and stored under these conditions, it should not be returned to the refrigerator and must be discarded if not used within the permitted period. Check the leaflet supplied with your medicine because local packaging instructions remain authoritative.

Side effects and warnings

Common adverse reactions in official product information include eye inflammation—particularly conjunctivitis—reactions at the injection site and dry eye. The US label also lists herpes zoster among common adverse reactions. Keratitis and allergic conjunctivitis can occur.

Seek urgent medical help for signs of a serious allergic reaction, such as breathing difficulty, swelling of the face, mouth or tongue, fainting, dizziness, widespread hives or a severe rash. Stop using the medicine until urgent advice is obtained.

Report new or persistent eye symptoms. Official information recommends assessment when conjunctivitis does not resolve with standard treatment or when symptoms suggest keratitis.

Vaccines and parasitic infections

Live and live-attenuated vaccines should not be given concurrently with Ebglyss. Age-appropriate vaccinations should be reviewed before treatment. Official labels also advise treating a pre-existing helminth infection before starting Ebglyss and reassessing treatment if an infection develops and does not respond to antihelminth therapy.

Pregnancy and breastfeeding

Human pregnancy data are limited. EU and UK information says it is preferable to avoid lebrikizumab during pregnancy as a precaution, while the US label describes insufficient human data to evaluate risk. Breastfeeding decisions require an individual assessment of benefit and potential risk. Discuss pregnancy plans and breastfeeding with the prescriber rather than applying one jurisdiction’s wording universally.

Ebglyss and Dupixent are different medicines

Dupixent (dupilumab) and Ebglyss are biologic medicines that may be used for atopic dermatitis, but they contain different antibodies, have different authorised indications across jurisdictions and use different schedules. They are not interchangeable. A clinician selects treatment using disease severity, age, weight, previous therapy, comorbid conditions and local authorisation or access criteria.

Missed dose or possible overdose

For a missed dose, current labels advise giving it as soon as possible and then resuming the scheduled dosing pattern. Confirm the next date with the prescriber or pharmacist if there is any uncertainty.

There is no specific antidote for lebrikizumab overdose in the official information reviewed. A person who receives more than prescribed should contact the treating service for monitoring and advice; do not take extra injections to correct a schedule without instructions.

Frequently asked questions

Official sources

This article was checked against current official EU, UK and US product information. The authorised wording and patient instructions in the reader’s jurisdiction take priority.

• European Medicines Agency: Ebglyss EPAR and EU product information
• UK SmPC: Ebglyss 250 mg pre-filled pen
• UK patient leaflet: Ebglyss 250 mg pre-filled pen
• US DailyMed: Ebglyss (lebrikizumab-lbkz) official label